Nowadly Craig D, Johnson M Austin, Hoareau Guillaume L, Manning James E, Daley James I
Department of Emergency Medicine David Grant United States Air Force Medical Center Travis Air Force Base Sacramento California USA.
Department of Emergency Medicine University of California at Davis Sacramento California USA.
J Am Coll Emerg Physicians Open. 2020 Aug 30;1(5):737-743. doi: 10.1002/emp2.12241. eCollection 2020 Oct.
Resuscitative endovascular balloon occlusion of the aorta (REBOA) has been proposed as a novel approach to managing non-traumatic cardiac arrest (NTCA). During cardiac arrest, cardiac output ceases and perfusion of vital organs is compromised. Traditional advanced cardiac life support (ACLS) measures and cardiopulmonary resuscitation are often unable to achieve return of spontaneous circulation (ROSC). During insertion of REBOA a balloon-tipped catheter is placed into the femoral artery and advanced in a retrograde manner into the aorta while the patient is undergoing cardiopulmonary resuscitation (CPR). The balloon is then inflated to fully occlude the aorta. The literature surrounding the use of aortic occlusion in non-traumatic cardiac arrest is limited to animal studies, case reports and one recent non-controlled feasibility trial. In both human and animal studies, preliminary data show that REBOA may improve coronary and cerebral perfusion pressures and key physiologic parameters during cardiac arrest resuscitation, and animal data have demonstrated improved rates of ROSC. Multiple questions remain before REBOA can be considered as an adjunct to ACLS. If demonstrated to be effective clinically, REBOA represents a potentially cost-effective and generalizable intervention that may improve quality of life for patients with non-traumatic cardiac arrest.
主动脉内复苏球囊阻断术(REBOA)已被提议作为一种治疗非创伤性心脏骤停(NTCA)的新方法。在心脏骤停期间,心输出量停止,重要器官的灌注受到损害。传统的高级心脏生命支持(ACLS)措施和心肺复苏往往无法实现自主循环恢复(ROSC)。在插入REBOA时,将带气囊导管经股动脉插入,并在患者进行心肺复苏(CPR)时逆行推进至主动脉。然后将球囊充气以完全阻断主动脉。关于在非创伤性心脏骤停中使用主动脉阻断的文献仅限于动物研究、病例报告和一项近期的非对照可行性试验。在人体和动物研究中,初步数据表明,REBOA可能会改善心脏骤停复苏期间的冠状动脉和脑灌注压以及关键生理参数,并且动物数据显示ROSC率有所提高。在将REBOA视为ACLS的辅助手段之前,仍有多个问题有待解决。如果在临床上被证明有效,REBOA代表了一种潜在的具有成本效益且可推广的干预措施,可能会改善非创伤性心脏骤停患者的生活质量。